Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Receivables (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Receivables for 8 consecutive years, with $3.8 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 1559.39% to $3.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Dec 2025, up 1559.39% year-over-year, with the annual reading at $3.8 million for FY2025, 1559.39% up from the prior year.
  • Receivables for Q4 2025 was $3.8 million at Precision Biosciences, roughly flat from $3.8 million in the prior quarter.
  • The five-year high for Receivables was $50.5 million in Q2 2022, with the low at $4000.0 in Q1 2025.
  • Average Receivables over 5 years is $4.6 million, with a median of $652000.0 recorded in 2023.
  • The sharpest move saw Receivables skyrocketed 10249.8% in 2022, then plummeted 98.97% in 2025.
  • Over 5 years, Receivables stood at $488000.0 in 2021, then surged by 47.54% to $720000.0 in 2022, then rose by 25.14% to $901000.0 in 2023, then tumbled by 74.58% to $229000.0 in 2024, then skyrocketed by 1559.39% to $3.8 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $3.8 million, $3.8 million, and $4000.0 for Q4 2025, Q3 2025, and Q1 2025 respectively.